BridgeBio Oncology Therapeutics reported cash from operations of -$44.36M and free cash flow of -$45.92M for the quarter ended Jun 2026, down 90.4% year over year. This cash flow statement covers 10 quarters of results from Mar 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | 1.14M | 2.29M | -17.11M | -19.63M | -21.15M | -28.02M | -49.18M | -43.41M | -46.18M | -60.19M |
| Share-based Compensation | 0.66M | 0.28M | 0.77M | 0.59M | 0.63M | 0.88M | 8.23M | 2.95M | 12.06M | 12.60M |
| Cash from Operations | -0.62M | -0.03M | -39.34M | -15.04M | -19.60M | -23.29M | -28.77M | -42.23M | -35.92M | -44.36M |
| Depreciation, Depletion & Amortization | ||||||||||
| Amortizatization of Intangibles | 1.54M | 0.41M | 0.39M | -0.58M | 1.04M | 0.07M | -0.41M | |||
| Change in Working Capital | ||||||||||
| Change in Account Payables | 1.96M | 0.54M | -2.05M | 2.09M | -2.42M | 10.69M | -5.33M | |||
| Change in Accured Expenses | 0.01M | 0.06M | 1.98M | 2.86M | 2.34M | 9.19M | -10.86M | 17.01M | -3.73M | 14.62M |
| Other Working Capital Changes | 0.02M | 0.05M | -0.12M | -0.12M | -0.13M | |||||
| Investing Activities | ||||||||||
| Capital Expenditures | -0.01M | 0.16M | 0.23M | 0.14M | 7.05M | -1.33M | 1.56M | |||
| Change in Acquisitions & Divestments | 25.57M | 39.96M | 43.85M | 45.16M | 28.88M | 26.26M | 53.31M | |||
| Cash from Investing Activities | -184.00M | 37.91M | 25.56M | 15.37M | 9.64M | 40.55M | 7.77M | -285.41M | 45.73M | |
| Financing Activities | ||||||||||
| Other financing activities | 5.09M | -4.03M | 373.46M | 0.42M | 0.04M | |||||
| Debt Issuance and Repayment | ||||||||||
| Long-Term Debt Issuances | 0.21M | |||||||||
| Change in Capital Stock | ||||||||||
| Net Shares Issued and Repurchased | 5.75M | 3.23M | ||||||||
| Net Equity Issued and Repurchased | 193.35M | 0.02M | -22.22M | 22.22M | ||||||
| Misc. | ||||||||||
| Cash from Financing Activities | 186.46M | 19.78M | 0.05M | -0.40M | 18.96M | 365.44M | -0.59M | 0.29M | 0.04M | |
| Change in Cash | 1.84M | -0.03M | 18.35M | 10.57M | -4.63M | 5.30M | 377.22M | -35.05M | -321.03M | 1.41M |
| Free Cash Flow | -0.62M | -0.03M | -39.34M | -15.03M | -19.76M | -23.52M | -28.91M | -49.28M | -34.59M | -45.92M |
| Net Cash Flow | 1.84M | -0.03M | 18.35M | 10.57M | -4.63M | 5.30M | 377.22M | -35.05M | -321.03M | 1.41M |